A Protein Degradation Approach to Overcome Paradoxical RAF Activation
CFT1946
oral mutant-selective BRAFV600X degrader Ph. I for BRAF-driven cancers from CRBN-based E3 recruiter + vemurafenib AACR, April 2023 C4 Therapeutics, Watertown, MA
oral mutant-selective BRAFV600X degrader Ph. I for BRAF-driven cancers from CRBN-based E3 recruiter + vemurafenib AACR, April 2023 C4 Therapeutics, Watertown, MA